Bone morphogenetic protein 2 stimulates chondrogenesis of equine synovial membrane-derived progenitor cells

Summary

Objectives: Bone morphogenetic protein 2 (BMP-2) is critical for skeletal and cartilage development, homeostasis and repair. This study was conducted to clone and characterize equine BMP-2, develop expression constructs for equine BMP-2, and to determine whether BMP-2 can stimulate chondrogenesis of equine synovial membrane-derived progenitor cells (SMPC).

Methods: Equine BMP-2 cDNA was amplified from chondrocyte RNA, and then transferred into an expression plasmid and adenoviral vector. Effective expression of equine BMP-2 was confirmed using a BMP reporter cell line. SMPC were isolated from synovium, expanded through two passages and transferred to chondrogenic cultures, with recombinant human (rh) transforming growth factor beta 1 (TGF-[uni03B2]1) or rhBMP-2. Chondro-genesis was assessed by up-regulation of collagen types II and X, and aggrecan mRNA, secretion of collagen type II protein and sulfated glycosaminoglycans (sGAG), and by alkaline phosphatase induction. Chondrogenic stimulation of SMPC by the equine BMP-2 adenovirus was assessed by sGAG secretion and histology.

Results: The mature equine BMP-2 peptide is identical to human and murine peptides. Recombinant human BMP-2 and TGF-[uni03B2]1 stimulated equivalent amounts of collagen type II protein in SMPC pellets, but sGAG secretion was doubled by BMP-2. Neither factor stimulated hypertrophic marker expression. The equine BMP-2 adenoviral vector induced chondrogenesis comparably to rhBMP-2 protein, with no indication of hypertrophy.

Clinical significance: Bone morphogenetic protein 2 is a potent inducer of SMPC nonhypertrophic chondrogenesis, supporting the use of this combination for articular cartilage repair applications.

Keywords

Equine BMP-2 - bone morphogenetic protein 2 - synovial membrane progenitor - chondro-genesis - adenoviral vector

• References

• 1 Urist MR. Bone formation by autoinduction. Science 1965; 150: 893-899.
• 2 Hogan BLM. Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Genes Dev 1996; 10: 1580-1594.
• 3 Kishigami S, Mishina Y. BMP signalling and early embryonic patterning. Cytokine Growth Factor Rev 2005; 16: 265-278.
• 4 Robert B. Bone morphogenetic protein signalling in limb outgrowth and patterning. Dev Growth Differ 2007; 49: 455-468.
• 5 Wang RN, Green J, Wang Z. et al. Bone morphogenetic protein (BMP) signalling in development and human diseases. Genes Dis 2014; 1: 87-105.
• 6 Griffith DL, Keck PC, Sampath TK. et al. Three-dimensional structure of recombinant human osteogenic protein 1: Structural paradigm for the transforming growth factor superfamily. Proc Natl Acad Sci U S A 1996; 93: 878-883.
• 7 Kang Q, Song W, Luo Q. et al. A comprehensive analysis of the dual roles of BMPs in regulating adipogenic and osteogenic differentiation of mesenchymal progenitor cells. Stem Cells Dev 2009; 18: 545-558.
• 8 Boden SD, Kang J, Sandhu HS. et al. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine 2002; 27: 2662-2673.
• 9 Swiontkowski MF, Aro HT, Donell S. et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: A prospective, controlled, randomized study of four hundred and fifty patients. J Bone Jt Surg 2006; 84-A: 2123-2134.
• 10 Jones AL. Recombinant human bone morphogenic protein-2 in fracture care. J Orthop Trauma 2005; 19: S23-S25.
• 11 Shimer AL, Oner FC, Vaccaro AR. Spinal reconstruction and bone morphogenetic proteins: Open questions. Injury 2009; 40 (Suppl. 03) S32-S38.
• 12 Faria MLE, Lu Y, Heaney K. et al. Recombinant human bone morphogenetic protein-2 in absorbable collagen sponge enhances bone healing of tibial osteotomies in dogs. Vet Surg 2007; 36: 122-131.
• 13 Milovancev M, Muir P, Manley P. et al. Clinical application of recombinant human bone morphogenetic protein-2 in 4 dogs. Vet Surg 2007; 36: 132-140.
• 14 Pinel CB, Pluhar GE. Clinical application of recombinant human bone morphogenetic protein in cats and dogs: A review of 13 cases. Can Vet J 2012; 53: 767-774.
• 15 Mrugala D, Dossat N, Ringe J. et al. Gene expression profile of multipotent mesenchymal stromal cells: Identification of pathways common to TGF-β/BMP2-induced chondrogenesis. Cloning Stem Cells 2009; 11: 1-15.
• 16 Rosen V, Nove J, Song JJ. et al. Responsiveness of clonal limb bud cell lines to bone morphogenetic protein 2 reveals a sequential relationship between cartilage and bone cell phenotypes. J Bone Miner Res 1994; 9: 1759-1768.
• 17 Tsumaki N, Nakase T, Miyaji T. et al. Bone morphogenetic protein signals are required for cartilage formation and differently regulate joint development during skeletogenesis. J Bone Miner Res 2002; 17: 898-906.
• 18 Lories RJU, Luyten FP. Bone morphogenetic protein signalling in joint homeostasis and disease. Cytokine Growth Factor Rev 2005; 16: 287-298.
• 19 Tsuji K, Bandyopadhyay A, Harfe BD. et al. BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing. Nat Genet 2006; 38: 1424-1429.
• 20 Stewart MC, Saunders KM, Burton-Wurster N. et al. Phenotypic stability of articular chondrocytes in vitro: The effects of culture models, BMP-2 and serum supplementation. J Bone Miner Res 2000; 15: 166-174.
• 21 Oshin AO, Caporali E, Byron CR. et al. Phenotypic maintenance of articular chondrocytes in vitro requires BMP activity. Vet Comp Orthop Traumatol 2007; 20: 185-191.
• 22 Dell’Accio F, De Bari C, El Tawil NM. et al. Activation of WNT and BMP signalling in adult human articular cartilage following mechanical injury. Arthritis Res Ther 2006; 8: R139.
• 23 Fukui N, Ikeda Y, Ohnuki T. et al. Pro-inflammatory cytokine tumor necrosis factor-alpha induces bone morphogenetic protein-2 in chondrocytes via mRNA stabilization and transcriptional up-regulation. J Biol Chem 2006; 281: 27229-27241.
• 24 Lories RJ, Daans M, Derese I. et al. Noggin haploinsufficiency differentially affects tissue responses in destructive and remodeling arthritis. Arthritis Rheum 2006; 54: 1736-1746.
• 25 Van Beuningen HM, Glansbeek HL, van der Kraan PM. et al. Differential effects of local application of BMP-2 or TGF-β1 on both articular cartilage composition and osteophyte formation. Osteoarthritis Cartilage 1998; 6: 306-317.
• 26 Sekiya I, Tao T, Hayashi M. et al. Periodic knee injections of BMP-7 delay cartilage degeneration induced by excessive running in rats. J Orthop Res 2009; 27: 1088-1092.
• 27 Scarfi S. Use of bone morphogenetic proteins in mesenchymal stem cell stimulation of cartilage and bone repair. World J Stem Cells 2016; 8: 1-12.
• 28 Sakaguchi Y, Sekiya I, Yagishita K. et al. Comparison of human stem cells derived from various mesenchymal tissues: Superiority of synovium as a cell source. Arthritis Rheum 2005; 52: 2521-2529.
• 29 De Bari C, Dell’Accio F, Tylanowski P. et al. Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum 2001; 44: 1928-1942.
• 30 Morito T, Muneta T, Hara K. et al. Synovial fluid-derived mesenchymal stem cells increase after intra-articular ligament injury in humans. Rheumatology 2008; 47: 1137-1143.
• 31 Kurth T, Hedborn E, Shintani N. et al. Chondrogenic potential of human synovial mesenchymal stem cells in alginate. Osteoarthritis Cartilage 2007; 15: 1178-1189.
• 32 Pei M, He F, Chen D. et al. Synovium-derived stem cell-based chondrogenesis. Differentiation 2008; 76: 1044-1056.
• 33 Zilberberg L, ten Dijke P, Sakai LY. et al. A rapid and sensitive bioassay to measure bone morphogenetic protein activity. BMC Cell Biol 2008; 8: 41.
• 34 Chen Y, Bianchessi M, Pondenis H. et al. Phenotypic characterization of equine synovial fluid-derived chondroprogenitor cells. Stem Cell Biol Res 2016; 3: 1.
• 35 Bianchessi M, Chen Y, Durgam S. et al. Effect of fibroblast growth factor 2 on equine synovial fluid chondroprogenitor expansion and chondrogenesis. Stem Cells Int 2016; 2016: 9364974.
• 36 Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-408.
• 37 Zhang H, Bradley A. Mice deficient for BMP2 are nonviable and have defects in amnion/chorion and cardiac development. Development 1996; 122: 2977-2986.
• 38 Salazar VS, Gamer LW, Rosen V. BMP signalling in skeletal development, disease and repair. Nat Rev Endocrinol 2016; 12: 203-221.
• 39 Shintani N, Hunziker EB. Chondrogenic differentiation of bovine synovium. Arthritis Rheum 2007; 56: 1869-1879.
• 40 Koga H, Shimaya M, Muneta T. et al. Local adherent technique for transplanting mesenchymal stem cells as a potential treatment of cartilage defect. Arthritis Res Ther 2008; 10: R84.
• 41 Pei M, Heyz F, Boycey BM. et al. Repair of full-thickness femoral condyle cartilage defects using allogeneic synovial cell-engineered tissue constructs. Osteoarthritis Cartilage 2009; 17: 714-722.
• 42 Aulin C, Jensen-Waern M, Ekman S. et al. Cartilage repair of experimentally induced osteochondral defects in New Zealand White rabbits. Lab Anim 2013; 47: 58-65.
• 43 Menendez I M, Clark DJ, Carlton M. et al. Direct delayed human adenoviral BMP-2 or BMP-6 gene therapy for bone and cartilage regeneration in a pony osteochondral model. Osteoarthritis Cartilage 2011; 19: 1066-1075.
• 44 Sellers RS, Zhang R, Glasson SS. et al. Repair of articular cartilage defects one year after treatment with recombinant human bone morphogenetic protein-2 (rhBMP-2). J Bone Joint Surg 2000; 82-A: 151-160.
• 45 Reyes R, Delgado A, Sánchez E. et al. Repair of an osteochondral defect by sustained delivery of BMP-2 or TGFβ1 from a bilayered alginate-PLGA scaffold. J Tissue Eng Regen Med 2014; 8: 521-533.
• 46 Di Cesare PE, Frenkel SR, Carlson CS. et al. Regional gene therapy for full-thickness articular cartilage lesions using naked DNA with a collagen matrix. J Orthop Res 2006; 24: 1118-1127.